Angel Ponferrada

Profesor Asociado

Universidad Complutense de Madrid

Spain

Research Interests

Explore related searches

Professors in Spain

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Angel Ponferrada is an Associated Professor at Universidad Complutense de Madrid, Spain. His research primarily focuses on inflammatory bowel disease, with recent publications examining the efficacy and safety of biologic therapies and the influence of familial history on treatment outcomes. He has contributed to several studies including the RAINBOW-IBD and ENEIDA registries, providing insights into the treatment dynamics of Crohn's disease and the management of pediatric-onset cases.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

SPAIN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Angel Ponferrada

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Frequency and Effectiveness of Dose Escalation and De-Escalation of Biologic Therapy in Inflammatory Bowel Disease: The RAINBOW-IBD Study of ENEIDA.

Influence of Familial Inflammatory Bowel Disease History on the Use of Immunosuppressants, Biological Agents and Surgery in Patients with Pediatric-Onset of the Disease in the Era of Biological Therapies. Results from the ENEIDA Registry

Influence of Familial Inflammatory Bowel Disease History on the Use of Immunosuppressants, Biological Agents and Surgery in Patients with Pediatric-Onset of the Disease in the Era of Biological Therapies. Results from the ENEIDA Registry

Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants With Moderately to Severely Active Crohn’s Disease: Results From the Phase 3 GRAVITI Study

HIV Infection Is Associated With a Less Aggressive Phenotype of Inflammatory Bowel Disease: A Multicenter Study of the ENEIDA Registry

Heterotaxia syndrome: when almost nothing is as it should be,Síndrome de heterotaxia: cuando casi nada es como debería ser

Ileal Predominance in Crohn's Disease Is Associated with Increased Intestinal Surgery and Biological Therapy Use, with Lower Treatment Persistence

Predictors of biologics/JAKi use, surgeries, and hospitalisations in a newly diagnosed cohort of IBD patients: Long-term outcomes from the nationwide EpidemIBD study of GETECCU

Subcutaneous Infliximab Cutoff Points in Patients With Inflammatory Bowel Disease: Data From the ENEIDA Registry

Influence of familial forms of inflammatory bowel disease on the use of immunosuppressants, biological agents, and surgery in the era of biological therapies. Results from the ENEIDA project.

Collaborators (6)

Jordi Guardiola

Manuel Van Domselaar

Manuel Barreiro de Acosta

Luis Fernández-Salazar

Pilar Nos

FRANCISCO RODRIGUEZ MORANTA

Make your next move.